The Russian Sputnik V vaccine is 92% effective in protecting people from Kovid-19. The Sovereign Wealth Fund made the claim on Wednesday, based on the results of the vaccine’s interim trial. Significantly, in the vaccine race Russia is trying to overtake Western countries and by August itself it had registered its Sputnik V vaccine. At the same time, the West continues to question the efforts of the Russia.
Trial on 16,000 volunteers
According to Reuters, two doses of the vaccine were administered in a trial involving 16,000 volunteers. The Russian Direct Investment Fund (RDIF) gave information on this. RDIF is involved in the development and global marketing of the vaccine. However, experts say there isn’t a lot of information on the trial design and protocol. In such a situation, it is difficult to say anything about the results.
Stories to hear
“We are saying based on the data that we have a very effective vaccine,” said Kirill Dmitriev, director of RDIF. He even added that it was such news that the developer of the vaccine will be telling generations to come. On the other hand, scientists have expressed concern over Moscow’s rapid progress and regulatory approval. Are they worried that the vaccine will need to be tested thoroughly before it is declared completely safe and effective?
6 month trial
RDIF said the Russian trial will last 6 months and its data will be published in the International Medical Journal after peer review. During the vaccine trial, 20 people received Kovid-19 and were then tested on the number of people who received the vaccine and the number of people who received plasibo.
Pfizer also announced
This figure was significantly lower than the 94 cases of infection found in the Pfizer and BioNTech vaccine trials. Pfizer later said it would continue the trial but later found 164 cases of Kovid-19. Let us know that Pfizer and BioNTech said on Monday that their vaccine was 90% effective.